"A comprehensive, multidisciplinary disease management center specializing in diseases of the liver, bile ducts, and pancreas."

During the past decade, The Liver Institute at Methodist Dallas Medical Center conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 17 clinical trials were completed, i.e. on average, 39.5% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 15 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Liver Institute at Methodist Dallas Medical Center" #1 sponsor was "Gilead Sciences" with 12 trials, followed by "Methodist Health System" with 8 trials sponsored, "Intercept Pharmaceuticals" with 5 trials sponsored, "CymaBay Therapeutics, Inc." with 4 trials sponsored and "Madrigal Pharmaceuticals, Inc." with 4 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Liver Institute at Methodist Dallas Medical Center" #1 collaborator was "Novo Nordisk A/S" with 2 trials as a collaborator, "Centocor, Inc." with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Novartis" with 1 trials as a collaborator and "Pharmaceutical Research Associates" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "The Liver Institute at Methodist Dallas Medical Center" are "Hepatitis C" (6 trials), "Nonalcoholic Steatohepatitis" (6 trials), "Primary Biliary Cholangitis" (4 trials), "Primary Sclerosing Cholangitis" (4 trials) and "Compensated Cirrhosis" (3 trials). Many other conditions were trialed in "The Liver Institute at Methodist Dallas Medical Center" in a lesser frequency.

Most popular intervention types in "The Liver Institute at Methodist Dallas Medical Center" are "Drug" (47 trials), "Other" (5 trials), "Procedure" (5 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Ribavirin" (4 trials), "Cilofexor" (3 trials), "Obeticholic Acid (OCA)" (3 trials) and "SEL" (3 trials). Other intervention names were less common.

The vast majority of trials in "The Liver Institute at Methodist Dallas Medical Center" are 57 trials for "All" genders.

Currently, there are NaN active trials in "The Liver Institute at Methodist Dallas Medical Center". undefined are not yet recruiting, 13 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 24 completed trials in The Liver Institute at Methodist Dallas Medical Center, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in The Liver Institute at Methodist Dallas Medical Center, 6 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".